117 related articles for article (PubMed ID: 23100300)
21. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells.
He W; Ye X; Huang X; Lel W; You L; Wang L; Chen X; Qian W
Int J Oncol; 2016 Apr; 48(4):1710-20. PubMed ID: 26892093
[TBL] [Abstract][Full Text] [Related]
22. Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis.
Puccetti E; Beissert T; Güller S; Li JE; Hoelzer D; Ottmann OG; Ruthardt M
Oncogene; 2003 Oct; 22(44):6900-8. PubMed ID: 14534537
[TBL] [Abstract][Full Text] [Related]
23. Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide.
Goussetis DJ; Altman JK; Glaser H; McNeer JL; Tallman MS; Platanias LC
J Biol Chem; 2010 Sep; 285(39):29989-97. PubMed ID: 20656687
[TBL] [Abstract][Full Text] [Related]
24. Autophagic degradation determines the fate of T315I-mutated BCR-ABL protein.
Shinohara H; Minami Y; Naoe T; Akao Y
Haematologica; 2019 May; 104(5):e191-e194. PubMed ID: 30467207
[No Abstract] [Full Text] [Related]
25. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.
le Coutre P; Mologni L; Cleris L; Marchesi E; Buchdunger E; Giardini R; Formelli F; Gambacorti-Passerini C
J Natl Cancer Inst; 1999 Jan; 91(2):163-8. PubMed ID: 9923858
[TBL] [Abstract][Full Text] [Related]
26. [Arsenic trioxide inhibits cell growth in imatinib-resistant bcr-abl mutant cell lines in vitro].
Lu RZ; Qiu L; Wang XD; Li XF; Chen LJ; Wang XL; Zhang BL; Ma J
Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):13-7. PubMed ID: 19563028
[TBL] [Abstract][Full Text] [Related]
27. A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges.
Sausville EA
J Natl Cancer Inst; 1999 Jan; 91(2):102-3. PubMed ID: 9923844
[No Abstract] [Full Text] [Related]
28. Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses.
Giafis N; Katsoulidis E; Sassano A; Tallman MS; Higgins LS; Nebreda AR; Davis RJ; Platanias LC
Cancer Res; 2006 Jul; 66(13):6763-71. PubMed ID: 16818652
[TBL] [Abstract][Full Text] [Related]
29. Delicious poison: arsenic trioxide for the treatment of leukemia.
Kwong YL; Todd D
Blood; 1997 May; 89(9):3487-8. PubMed ID: 9129058
[No Abstract] [Full Text] [Related]
30. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.
Yang K; Fu LW
Crit Rev Oncol Hematol; 2015 Mar; 93(3):277-92. PubMed ID: 25500000
[TBL] [Abstract][Full Text] [Related]
31. Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation.
Wetzler M; Brady MT; Tracy E; Li ZR; Donohue KA; O'Loughlin KL; Cheng Y; Mortazavi A; McDonald AA; Kunapuli P; Wallace PK; Baer MR; Cowell JK; Baumann H
Clin Cancer Res; 2006 Nov; 12(22):6817-25. PubMed ID: 17121903
[TBL] [Abstract][Full Text] [Related]
32. Chronic myelogenous leukaemia--new therapeutic principles.
O'Dwyer ME; Druker BJ
J Intern Med; 2001 Jul; 250(1):3-9. PubMed ID: 11454136
[TBL] [Abstract][Full Text] [Related]
33. Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein.
Elzinga BM; Nyhan MJ; Crowley LC; O'Donovan TR; Cahill MR; McKenna SL
Am J Hematol; 2013 Jun; 88(6):455-62. PubMed ID: 23440701
[TBL] [Abstract][Full Text] [Related]
34. SnoN/SkiL, a TGFβ signaling mediator: a participant in autophagy induced by arsenic trioxide.
Raffoul F; Campla C; Nanjundan M
Autophagy; 2010 Oct; 6(7):955-7. PubMed ID: 20699661
[TBL] [Abstract][Full Text] [Related]
35. [Effects of As2O3 on the BCR/ABL protein tyrosine phosphorylation in K562 cells].
Xiao D; Sun G; Su H
Zhonghua Xue Ye Xue Za Zhi; 1999 Dec; 20(12):637-9. PubMed ID: 11721366
[TBL] [Abstract][Full Text] [Related]
36. MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells.
Wong SM; Liu FH; Lee YL; Huang HM
PLoS One; 2016; 11(1):e0148093. PubMed ID: 26815740
[TBL] [Abstract][Full Text] [Related]
37. Rho-signaling pathways in chronic myelogenous leukemia.
Kuzelová K; Hrkal Z
Cardiovasc Hematol Disord Drug Targets; 2008 Dec; 8(4):261-7. PubMed ID: 19075636
[TBL] [Abstract][Full Text] [Related]
38. Arsenic trioxide induces apoptosis in chronic myelogenous leukemia K562 cells: possible involvement of p38 MAP kinase.
Shim MJ; Kim HJ; Yang SJ; Lee IS; Choi HI; Kim T
J Biochem Mol Biol; 2002 Jul; 35(4):377-83. PubMed ID: 12296996
[TBL] [Abstract][Full Text] [Related]
39. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
[TBL] [Abstract][Full Text] [Related]
40. Emodin Exerts an Antiapoptotic Effect on Human Chronic Myelocytic Leukemia K562 Cell Lines by Targeting the PTEN/PI3K-AKT Signaling Pathway and Deleting BCR-ABL.
Wang CG; Zhong L; Liu YL; Shi XJ; Shi LQ; Zeng L; Liu BZ
Integr Cancer Ther; 2017 Dec; 16(4):526-539. PubMed ID: 27698265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
